Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
ApexOnco Front Page
Recent articles
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
But camizestrant’s use could depend on uptake of monitoring – for now.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
